Action Quoin Pharmaceuticals - QNRX

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

0,3035

Prix Achat

0,3005

Prix Vente

0,3098

Volume échangé

9 445

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

1,533M

Clôture Veille

0,3098

Ouverture

Dernière Transaction

0.3095

Dernière heure de transaction

12:11:05

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

5 049 720

Rendement du Dividende

Ratio Cours sur Bénéfices

0,00

Bénéfice par action (BPA)

Chiffre d'affairess

Bénéfice net

-8,69M

Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Neth... Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others. Show more

Secteur

Medicinal Chems,botanicl Pds

Industrie

Cmp Programming,data Process

Site Web

www.cellect.co

Siège social

Kfar Saba, Center, Isr

Fondé

2007

Quoin Pharmaceuticals Ltd est coté dans le secteur Medicinal Chems,botanicl Pds de la NASDAQ avec le ticker QNRX. Le dernier cours de clôture d'Quoin Pharmaceuticals était de US$0,31. Au cours de la dernière année, les actions de Quoin Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

Quoin Pharmaceuticals compte actuellement 5 049 720 actions en circulation. La capitalisation boursière d'Quoin Pharmaceuticals est de US$1,56 million.

Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025

ASHBURN, Va., March 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or...

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Target Indications Include Microcystic Lymphatic Malformations, Venous Malformations and AngiofibromasProprietar...

Form 8-K - Current report

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Groundbreaking data from first whole body application of QRX003 underscores potential efficacyTransformational...

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the...

Form 8-K - Current report

Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Multi-pronged media campaign to raise awareness about the disease and its impact on patients, family members...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 8-K - Current report

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

QNRX - Frequently Asked Questions (FAQ)

What is the current Quoin Pharmaceuticals share price?

The current share price of Quoin Pharmaceuticals is US$ 0,3035

How many Quoin Pharmaceuticals shares are in issue?

Quoin Pharmaceuticals has 5 049 720 shares in issue

What is the market cap of Quoin Pharmaceuticals?

The market capitalisation of Quoin Pharmaceuticals is USD 1,56M

What is the 1 year trading range for Quoin Pharmaceuticals share price?

Quoin Pharmaceuticals has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the reporting currency for Quoin Pharmaceuticals?

Quoin Pharmaceuticals reports financial results in USD

What is the latest annual profit for Quoin Pharmaceuticals?

The latest annual profit of Quoin Pharmaceuticals is USD -8,69M

What is the registered address of Quoin Pharmaceuticals?

The registered address for Quoin Pharmaceuticals is 23 HATA’AS STREET, KFAR SABA, CENTER, 44425

What is the Quoin Pharmaceuticals website address?

The website address for Quoin Pharmaceuticals is www.cellect.co

Which industry sector does Quoin Pharmaceuticals operate in?

Quoin Pharmaceuticals operates in the CMP PROGRAMMING,DATA PROCESS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
RDFNRedfin Corporation	US$ 10,16 (74,57%)	7,37M
STSSSharps Technology Inc	US$ 0,5119 (72,53%)	73,69M
CKPTCheckpoint Therapeutics Inc	US$ 4,14 (67,61%)	2,05M
MLYSMineralys Therapeutics Inc	US$ 17,10 (62,55%)	906,8k
LGHLWLion Group Holding Ltd	US$ 0,01 (56,25%)	7
LEGHLegacy Housing Corporation	US$ 16,48 (-34,16%)	7
GEOSGeospace Technologies Corporation	US$ 5,33 (-28,65%)	15
ABLVAble View Global Inc	US$ 1,30 (-25,29%)	223,47k
XMTRXometry Inc	US$ 19,01 (-22,82%)	17
SUNESUNation Energy Inc	US$ 0,3161 (-20,68%)	3,38M
STSSSharps Technology Inc	US$ 0,5119 (72,53%)	73,69M
ICONIcon Energy Corporation	US$ 0,1937 (14,75%)	34,95M
BTOGBit Origin Ltd	US$ 0,5271 (-14,98%)	27,25M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 10,09 (-5,35%)	8,27M
RDFNRedfin Corporation	US$ 10,16 (74,57%)	7,37M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Quoin Pharmaceuticals Ltd (QNRX)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Quoin Pharmaceuticals Ltd

QNRX Dernières nouvelles

Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Form 8-K - Current report

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Form 8-K - Current report

Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 8-K - Current report

Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Form 8-K - Current report

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Form 8-K - Current report

Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

QNRX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Quoin Pharmaceuticals Ltd (QNRX) Cours

Quoin Pharmaceuticals Ltd (QNRX)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Quoin Pharmaceuticals Ltd

QNRX Dernières nouvelles

Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Form 8-K - Current report

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Form 8-K - Current report

Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 8-K - Current report

Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Form 8-K - Current report

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Form 8-K - Current report

Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

QNRX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR